IP Library Granted Patent US 7,067,483
Granted Patent B2
US 7,067,483 · App. 10/931,122 · Granted Jun 27, 2006

Pharmaceutical compositions containing a gycopeptide antibiotic and a cyclodextrin

Assignee: Theravance, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,067,483
App. No.
10/931,122
Granted
Jun 27, 2006
Kind
B2
Abstract

Disclosed are pharmaceutical composition containing a cyclodextrin and a therapeutically effective amount of a glycopeptide antibiotic or a salt thereof. Also disclosed are methods of treating a bacterial disease in a mammal by administering said pharmaceutical composition.

Claims (12)

1. A method for reducing tissue accumulation of a lipidated glycopeptide antibiotic in a mammal, the method comprising administering a therapeutically effective amount of the lipidated glycopeptide antibiotic or a pharmaceutically acceptable salt thereof to the mammal in a pharmaceutical composition comprising a cyclodextrin, wherein the lipidated glycopeptide antibiotic accumulates in the mammal in the absence of the cyclodextrin.

2. The method of claim 1 , wherein the pharmaceutical composition further comprises water.

3. A method for reducing tissue accumulation of a lipidated glycopeptide antibiotic in a mammal, the method comprising administering a therapeutically effective amount of the lipidated glycopeptide antibiotic or a pharmaceutically acceptable salt thereof to the mammal in a pharmaceutical composition comprising

an aqueous cyclodextrin carrier,

wherein the lipidated glycopeptide antibiotic accumulates in the mammal in the absence of the cyclodextrin.

4. A method for reducing tissue accumulation of a lipidated glycopeptide antibiotic in a mammal, the method comprising administering a therapeutically effective amount of the lipidated glycopeptide antibiotic or a pharmaceutically acceptable salt thereof to the mammal in a pharmaceutical composition comprising

1 to 40 weight percent of a cyclodextrin; and

60 to 99 weight percent of water, based on 100 weight percent of the composition, wherein the lipidated glycopeptide antibiotic accumulates in the mammal in the absence of the cyclodextrin.

5. The method of claim 4 , wherein the cyclodextrin comprises about 5 to 35 weight percent of the composition.

6. The method of claim 4 , wherein the cyclodextrin comprises about 10 to 30 weight percent of the composition.

7. The method of any one of claims 1 to 6 , wherein the cyclodextrin is hydroxypropyl-α-cyclodextrin.

8. The method of any one of claims 1 to 6 , wherein the cyclodextrin is sulfobutyl ether β-cyclodextrin.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 14, 2018
From: THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC
To: CUMBERLAND PHARMACEUTICALS INC.
Reel/Frame 047909/0853 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 10, 2014
From: THERAVANCE, INC.
To: THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC
Reel/Frame 033179/0422 →
Continuity (9)
Continuation 0984689300 · May 1, 2001
Provisional Application 6022672700 · Aug 18, 2000
Provisional Application 6021342800 · Jun 22, 2000
Provisional Application 6021314600 · Jun 22, 2000
Provisional Application 6021341700 · Jun 22, 2000
Provisional Application 6021341000 · Jun 22, 2000
Provisional Application 6021341500 · Jun 22, 2000
Provisional Application 6020117800 · May 2, 2000
Related Publication 20050032676A1 · Feb 10, 2005